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Analysis of Human Immunodeficiency Virus Type 1 Drug Resistance
in Children Receiving Nucleoside Analogue Reverse-Transcriptase Inhibitors
plus Nevirapine, Nelfinavir, or Ritonavir (Pediatric AIDS Clinical Trials
Group 377)
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J. Brooks Jackson,1 You-Gan Wang,3 Sophia Lee,3
Lee-Jen Wei,3 Shawn Cunningham,1 Michael Wantman,3
Andrew Wiznia,4 George Johnson,6 Sharon Nachman,5
and Paul Palumbo7
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Department of Pathology, Johns Hopkins Medical Institutions,
Baltimore, Maryland; 2Department of Pediatrics, University
of California, Los Angeles School of Medicine, Los Angeles;
3
Statistical Data Analysis Center, Harvard School of Public Health,
Boston, Massachusetts; 4Department of Pediatrics, Jacobi Medical
Center, Albert Einstein College of Medicine, Bronx, and 5Department
of Pediatrics, State University of New York, Stony Brook;
6
Department of Pediatrics, Medical University of South Carolina,
Charleston; 7Department of Pediatrics, University of Medicine
and Dentistry of New Jersey, Newark

In Pediatric AIDS Clinical Trials Group 377, antiretroviral therapy–experienced children were
randomized to 4 treatment arms that included different combinations of stavudine, lamivudine
(3TC), nevirapine (Nvp), nelfinavir (Nfv), and ritonavir (Rtv). Previous treatment with zidovudine (Zdv), didanosine (ddI), or zalcitabine (ddC) was acceptable. Drug resistance (R) mutations were assessed before study treatment (baseline) and at virologic failure. ZdvR, ddIR, and
ddCR mutations were detected frequently at baseline but were not associated with virologic
failure. Children with drug resistance mutations at baseline had greater reductions in virus load
over time than did children who did not. NvpR and 3TCR mutations were detected frequently
at virologic failure, and NvpR mutations were more common among children receiving 3-drug
versus 4-drug Nvp-containing regimens. Children who were maintained on their study regimen
after virologic failure accumulated additional NvpR and 3TCR mutations plus RtvR and NfvR
mutations. However, RtvR and NfvR mutations were detected at unexpectedly low rates.

Treatment with highly active antiretroviral therapy (HAART)
can prolong the lives and improve the health of patients with
human immunodeficiency virus type 1 (HIV-1) infection. However, the emergence of drug-resistant HIV-1 can limit the efficacy
of antiretroviral treatment regimens and a patient’s treatment
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options [1, 2]. Most studies of antiretroviral drug resistance have
been in adults [3–5]; however, those results may not be directly
applicable to pediatric cohorts, since factors that influence selection of drug-resistant variants may be different in children.
Such factors include the heterogeneity of HIV-1 variants in the
virus pool before drug therapy, the potential for the patient to
have been infected with drug-resistant HIV-1, the pharmacokinetics of antiretroviral drugs across different age groups, and
unique barriers to adherence to treatment regimens.
Limited studies in children have confirmed that drug-resistant HIV-1 can emerge during antiretroviral therapy [6, 7] and
that emergence of drug-resistant HIV-1 can affect clinical outcome [8]. The number of children who have drug-resistant HIV1 before initiating antiretroviral therapy probably has increased
in recent years, since the use of antiretroviral drugs to prevent
vertical transmission has become the standard of care [9–11].
An increasing number of children in developed nations probably have acquired drug-resistant HIV-1, since antiretroviral
use has increased, typically as sequential courses of 1- or 2drug regimens. Infection of a child with drug-resistant HIV-1
by horizontal transmission also has been reported [12].
Here we examined HIV-1 drug resistance in stable, antiretroviral therapy–experienced HIV-infected children enrolled in
a randomized, open-label, multiarm controlled trial, Pediatric
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AIDS Clinical Trials Group Protocol (PACTG) 377 [13]. Children in PACTG 377 were randomized to treatment arms that
included different combinations of stavudine (d4T), lamivudine
(3TC), nevirapine (Nvp), nelfinavir (Nfv), or ritonavir (Rtv) (table 1). Children were followed up for ⭐96 weeks for analysis of
safety, tolerance, and virologic response. Of the children, 57%
had satisfactory initial virologic suppression (see below). The
proportion of children who were maintained on their initial study
therapy and had sustained HIV-1 RNA suppression (⭐400 copies/mL) at week 48 was significantly higher for study arm D,
which suggests that the 4-drug combination prolonged the benefits of antiretroviral therapy (P.K., unpublished data).
We evaluated the prevalence of drug resistance mutations in
the children before study treatment and the impact of these
mutations on virologic response to treatment. We also evaluated
Table 1.
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whether there was additional selection of drug resistance mutations in children who experienced virologic failure and
whether selection was less common in children who received
the 4-drug regimen. This is the largest study to date of HIV-1
drug resistance in children and the first to examine drug resistance in a large pediatric cohort in the context of a randomized,
controlled trial of HAART.

Materials and Methods
Quantification of HIV-1 RNA. HIV-1 RNA copy numbers (virus loads) were measured by using the Amplicor HIV-1 Monitor
Test kit (Roche Diagnostic Systems), with an assay quantification
limit of 400 copies/mL.
HIV-1 genotyping. HIV-1 genotyping was done by using the

Resistance mutations detected in Pediatric AIDS Clinical Trials Group 377, by trial arm and outcome.

Resistance
mutation
Reverse transcriptase
M41L
E44D
D67N
T69D
K70R
L74V
V75T
K103N
V106A
V108I
V118I
Q151M
Y181C
M184I
M184V
Y188L
G190A
L210W
T215F
T215Y
K219Q
Protease inhibitor
L10I
K20R
D30N
L33F
M36I
M46I
M46L
I54V
A71V
A71T
V77I
V82A
I84V
N88D
L90M

Arm A

Arms B ⫹ Q

Arm C

Arm D

d4T ⫹ Nvp ⫹ Rtv

d4T ⫹ 3TC ⫹ Nfv

d4T ⫹ Nvp ⫹ Nfv

d4T ⫹ 3TC ⫹ Nvp ⫹ Nfv

Baseline
(n p 32)

Failure
(n p 17)

Late
failure
(n p 9)

13
2
5

4

3

2

2

5
3

3
1

3

1

12
1

7
1

3
5
2

7
1
13
3
2

6

Failure
(n p 19)

Late
failure
(n p 11)

19
4
10

6

5

2
2
5
1

1
1
2

11
8
1

Baseline
(n p 30)

Failure
(n p 16)

Late
failure
(n p 12)

10
3
9

4

5

5
1
4
2
1
7
1

4
1
2
1
1
6

2
1
8
1

2
1
6

6
6
1

11

3

2

7
1

1

14

10

1

5

1
1
3
2

1
1

7
1

4
1

1

3

Baseline
(n p 49)

1
1
1

1
7
3
9
4

5
4
1
5
1

1
1
1

2
1

2

1
3
1

7

1

2
1
11

12
5
16
8

3
2
6
2

3

3
1

2

3
1

1

5
1

1
3
3
5

Baseline
(n p 24)

Failure
(n p 7)

Late
failure
(n p 3)

10
1
5

2

1

1
1
1

1
1

1
1

2
1

1

1

3

2

2

1
1

5
4

2
2

7
3
10
4

2
1

1

2

1
1
3

3

3

3

1

4

2

1

1

1

1
1
8

1
5
1

2
3
3
1

2
12

2

2

5

6

1
4

8

2
6

1
1

2
1

NOTE. Data are no. of times each mutation was detected in samples of the study arms. The number of children analyzed at each time point in each study arm
is shown (n). Data from study arms B and Q are combined; arms B and Q differed in the frequency of Nfv dosing. 3TC, lamivudine; d4T, stavudine; Nfv, nelfinavir;
Nvp, nevirapine; Rtv, ritonavir.
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ViroSeq HIV-1 Genotyping System (Applied Biosystems). In some
cases, the amount of plasma available for analysis was limited, and
genotyping was done with less than the recommended 0.5 mL of
plasma. In this system, HIV-1 RNA is extracted from plasma samples and reverse transcribed with murine Moloney leukemia virus
reverse transcriptase (RT). A 1.8-kb DNA fragment is then amplified in the same tube in a single 40-cycle polymerase chain reaction (PCR) with AmpliTaq gold polymerase and uracil N-deglycosylase decontamination control. PCR products are purified
by using spin columns, analyzed by agarose gel electrophoresis,
and sequenced with premixed BigDye sequencing reagents in 7
separate reactions. Sequencing products were analyzed by using an
ABI 310 or ABI 377 automated sequencer. The resulting sequences
were assembled and were analyzed with HIV-1 Genotyping System
software (see below).
Phylogenetic analysis. Protease and RT nucleotide sequences
(297 and 972 nt, respectively) were aligned. Phylogenetic reconstructions were performed with PHYLIP 3.572c (J. Felsenstein,
University of Washington, Seattle), using the neighbor-joining
method. Reference sequences were obtained from the 1999 HIV-1
Subtype Reference Alignments of the Los Alamos National Laboratory (http://hiv-web.lanl.gov/), including laboratory strains
pNL4-3 and HXB2. There was no evidence of contamination with
strains pNL4-3 or HXB2, which were present in some of the genotyping laboratories. Furthermore, sequences from samples derived
from individual children collected at different times clustered more
closely with one another than with sequences from other children
in the study, and no 2 sequences were identical. Therefore, it is
unlikely that samples were cross-contaminated (e.g., during PCR)
or were misidentified.
Analysis of drug resistance mutations. Mutations associated
with resistance to antiretroviral drugs were identified by using the
HIV-1 Genotyping Software package v2.1 or v2.2 (Applied Biosystems). Analysis was focused on primary and secondary HIV-1
drug resistance mutations described in a recent consensus report
[2]. These mutations and the drugs with which they are associated
are as follows (primary mutations are denoted with an asterisk):
d4T, V75T; 3TC, E44D*, V118I*, and M184V*; Nvp, L100I,
K103N*, V106A*, V108I*, Y181C/I*, Y188C/H/L*, and G190A*;
Rtv, K20M/R, V32I, L33F, M36I, M46I/L, I54L/V, A71T/V, V77I,
V82A/F/S/T,* I84V, and L90M; Nfv, L10F/I, D30N*, M36I, M46I/
L, A71T/V, V77I, V82A/F/S/T*, I84V, N88D, and L90M*; zidovudine (Zdv), M41L, D67N, K70R*, L210W, T215F/Y*, and
K219Q; didanosine (ddI), K65R, L74V*, and M184I/V; zalcitabine
(ddC), K65R*, T69D*, L74V*, and M184I/V*; and multinucleoside, Q151M, 69 insertion.
Sequences were obtained for protease (aa 1–99) and RT (aa
1–324). Drug resistance mutations present as amino acid mixtures
were identified only if the corresponding nucleotide mixture was
present in the sequences of both DNA strands. Sequences from
both DNA strands were obtained for the entire region analyzed
for 214 (93%) of 229 samples.
Statistical analysis. Genotyping data were transmitted electronically to a central data management center and were entered
into a central database. Statistical analysis was performed at the
ACTG Statistical Data Analysis Center (Boston). Results presented in table 2 are based on the Wilcoxon test. The Wei-Johnson
statistical technique [14] was used to combine the dependent tests

JID 2001;183 (15 June)

Table 2. Comparison of mean change in virus load among children
who did and did not have primary drug resistance mutations at baseline.
Reduction in virus load
Children, week
All
8
12
24
36
48
d
Received Nvp
8
12
24
36
48
e
Did not receive Nvp
8
12
24
36
48

Mutation(s)
present

a

Mutations(s)
absent

b

95% CI

c

P

1.7
1.6
1.7
1.8
1.9

(91)
(88)
(75)
(71)
(71)

1.0
1.2
1.1
1.2
1.3

(29)
(31)
(24)
(21)
(23)

0.3–1.2
0–0.9
0.2–1.2
0.1–1.1
0.1–1.1

.002
.048
.005
.024
.014

1.8
1.6
1.7
1.7
1.7

(51)
(50)
(45)
(43)
(41)

1.0
1.0
1.0
1.1
1.3

(21)
(23)
(17)
(17)
(18)

0.4–1.4
0.2–1.2
0.08–1.2
0.1–1.1
0.03–0.9

!.001

1.5
1.5
1.8
1.9
2.1

(40)
(38)
(30)
(28)
(30)

1.1
1.5
1.1
1.8
1.4

(8)
(8)
(7)
(4)
(5)

⫺0.3
⫺0.8
⫺0.3
⫺1.0
⫺0.4

to
to
to
to
to

1.3
0.9
1.6
1.3
1.5

.011
.014
.026
.100
.226
.933
.129
.739
.178

NOTE. Data are no. of mutations (no. of children), unless otherwise indicated. Nvp, nevirapine.
a
Mean decrease in log10 RNA copies/mL from baseline at each time point.
Mean baseline virus loads for children with or without ⭓1 primary resistance
mutation at baseline were 4.6 and 4.4 log10 RNA copies/mL, respectively.
b
95% Confidence intervals (CIs) for difference of means.
c
Two-sided P values.
d
Study arms A, C, and D.
e
Study arms B and Q.

at weeks 8, 12, 24, 36, and 48. Multifactorial simulation “hotspot”
analysis was done as described elsewhere [15].
GenBank accession numbers. GenBank accession numbers for
the HIV-1 sequences analyzed in this report are as follows: baseline
sequences, AF357605–AF357739; failure sequences, AF357740–
AF357798; and late failure sequences, AF357799–357833.

Results
PACTG 377 Patient Cohort

In total, 181 children aged 4 months to 17 years were enrolled
in PACTG 377 from December 1997 through September 1998.
Previous treatment with Zdv, ddC, or ddI was acceptable: 35%
had previous treatment with ddI, 60% with Zdv/ddI, and 5%
with other drug combinations. Children were randomized to
the study arms shown in table 1. In PACTG 377, satisfactory
initial virologic suppression was defined as plasma HIV-1 RNA
level ⭐400 copies/mL or a decrease in RNA that was both ⭓2
log10 copies/mL below baseline and !10,000 copies/mL on ⭓ 2
of the 3 RNA determinations done at weeks 8, 12, and 16 [13].
Subsequent virologic failure was defined as an RNA value
110,000 copies/mL that also was a 0.75 log10 increase above
the RNA nadir (the average of the log10 transformation of the
2 lowest RNA determinations at weeks 8, 12, and 16) [13]. In
PACTG 377, children were divided into failure and nonfailure
groups on the basis of their virologic response to their PACTG
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377 treatment regimen. The nonfailure group included children
who had satisfactory initial virologic suppression with sustained
virologic suppression for the duration of the study period (to
week 48). The failure group included children who did not
achieve satisfactory initial virologic suppression or who had
subsequent virologic failure.

PACTG 377 Patient Subcohort in Resistance Analysis

HIV-1 genotyping was done by using plasma samples collected
at 3 different time points: baseline, failure, and late failure, as
defined below. All available samples from each time point were
analyzed. Of the 181 children in PACTG 377, 141 had ⭓1 plasma
sample available for resistance studies. This included 71 children
in the nonfailure group and 70 children in the failure group. In
total, 229 samples were analyzed, including 135 baseline samples,
59 failure samples, and 35 late failure samples. The subcohort
of patients analyzed in this report (n p 141 ) were of similar age
and had similar baseline virus loads, baseline CD4 cell counts,
and previous treatment histories, compared with those in 181
children enrolled in PACTG 377. This also was the case for the
individual study arms.

Analysis of Baseline Samples

In PACTG 377, plasma samples were collected before the initiation of antiretroviral study treatment (baseline samples). Baseline samples were available for genotypic analysis from 135 of
141 children, including samples from 71 (75%) of 95 children in
the nonfailure group and 64 (76%) of 84 children in the failure
group. Protease and RT sequences obtained from genotypic analysis of baseline samples were analyzed for the presence of primary
drug resistance mutations associated with PACTG 377 study
drugs (3TC, d4T, Nvp, Nfv, and Rtv) and for nonstudy drugs
that the children might have received before enrollment in the
trial (Zdv, ddI, and ddC). We observed a high rate of primary
drug resistance mutations at baseline in both the failure and
nonfailure groups. However, there was no significant difference
between the rate of mutations associated with resistance to nonstudy drugs or study drugs in the failure versus nonfailure groups.
Analysis of specific mutations is described below.
Baseline mutations associated with resistance to nonstudy
drugs. At study entry, many children had baseline mutations
associated with resistance to nonstudy drugs (table 1), which is
consistent with previous exposure to nucleoside RT inhibitors.
Of note, most of these mutations were associated with Zdv resistance mutations (ZdvR), which also are recognized increasingly
as playing a role in resistance to d4T. Furthermore, 30 (47%) of
64 children in the failure group and 39 (55%) of 71 children in
the nonfailure group had ⭓2 ZdvR mutations. There was no
significant difference between the number of baseline ZdvR mutations in the failure group and that in the nonfailure groups
(P p .39, Fisher’s exact text). Furthermore, the presence of any
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single ZdvR mutation or of ⭓2 ZdvR mutations at baseline was
not predictive of virologic failure. Mutations associated with ddIR
or ddCR also were detected at baseline but were not associated
with virologic failure in this cohort. Specifically, the presence of
the M184V mutation, which also confers resistance to the study
drug 3TC, was not predictive of virologic failure in the 3TCcontaining treatment arms (see below).
Baseline mutations associated with resistance to study drugs.
Primary mutations associated with resistance to drugs included
in the study also were detected at baseline (table 1). Of these 43
mutations, 37 (86%) were associated with resistance to 3TC
(E44D, V118I, and M184V). The M184V mutation, which may
have been selected during previous ddI or ddC treatment, was
identified in only 4 (3%) of 135 children. In contrast, the E44D
and V118I mutations were identified at baseline in 10 (7%) and
23 (17%) of 135 children, respectively. The latter 2 mutations
probably were selected for by previous treatment with Zdv in
combination with ddI [16]. Those mutations (E44D and V118I)
have been associated with low-to-moderate cross-resistance to
3TC when ZdvR mutations also are present [16]. Of the 79 children who received a 3TC-containing regimen in PACTG 377, 16
had the E44D and/or V118I mutation and ⭓1 ZdvR mutation
at baseline. There was no significant difference in the frequency
of this mutation pattern at baseline among the failure and nonfailure groups among children who received 3TC (69% and 51%,
respectively; P p .26, Fisher’s exact test). In addition to the mutations described above, we identified 4 children with NvpR mutations (K103N, V108I, and G190A) at baseline and 2 children
with the L90M mutation associated with NfvR. The protease
polymorphisms V77I and M36I were detected in many of the
baseline samples. However, there was no significant difference
between the frequency of these polymorphisms in the failure
group and those in the nonfailure group, or among any of the
treatment arms (A, B, C, or D, pairwise comparisons).
Relationship of baseline genotype to virus load. We first
examined whether the presence of individual primary drug resistance mutations at baseline correlated with virus load at time
of virologic failure. The only finding of statistical significance
was that the 8 children who had the V118I mutation at baseline
had slightly lower mean virus loads at failure than did the 54
children who did not have this mutation (4.5 log10 and 4.0 log10
RNA copies/mL, respectively; P p .04 ). The clinical significance of this finding is not clear. We found no significant difference in the mean virus load at failure between children who
had the E44D and/or V118I mutation in the context of ⭓1
ZdvR mutation and those who did not have those mutations
at baseline.
We next compared the reduction in virus load during the
treatment period among children who did and did not have ⭓1
primary drug resistance mutation at baseline. Ten children for
whom study treatment was changed or discontinued before
week 8 were excluded from this analysis. Those children were
withdrawn from the study because of drug intolerance or for
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other clinical reasons (virologic data were not available until
study week 12). At each time point, a linear regression model
with baseline RNA adjustment was used for analyzing the reduction of virus load (log10 RNA; table 2). We also analyzed
virus loads over time, combining results from weeks 8, 12, 24,
36, and 48. Results for the 2-sided combined test were highly
significant (P ! .001). Our analysis indicates that the reduction
in virus load over the course of the 48-week study was consistently greater for children who had ⭓1 primary resistance mutation at baseline than for those who did not. This effect also
was observed in children who received Nvp-containing regimens in PACTG 377 but not in children who did not receive
Nvp (table 2).

Analysis of Failure Samples

We next examined whether resistance mutations were selected
in children who experienced virologic failure. We analyzed samples collected at week 12 from children who failed to attain
satisfactory initial virologic suppression and samples collected
at later times from children who initially attained virologic suppression but had subsequent rebound in HIV-1 load. Of the 70
children, virologic failure time (time of sample collection) occurred at week 12 for 59 (84%), at week 24 for 3 (4%), at week
36 for 7 (10%), and at week 48 for 1 (1%) (median, 12 weeks;
range, 12–48 weeks).
Mutations associated with resistance to nonstudy drugs that
were identified at the time of virologic failure included those
associated with ZdvR and ddIR or ddCR. There was no significant difference between the frequency of any of these mutations
in the baseline and failure samples. In contrast, 47 (81%) of 58
children had ⭓1 primary resistance mutation to a study drug
at the time of virologic failure versus 16 (25%) of 64 children
at baseline. That difference was highly significant (P ! .0001,
Fisher’s exact test). The majority of these mutations were associated with 3TCR (V118I and M184V) and NvpR (K103N,
V106A, Y181C, Y188L, and G190A). In contrast, mutations
associated with NfvR (D30N and V82A) and RtvR (V82A) were
detected rarely at the failure time point (table 1). When we
analyzed the 52 children who had both baseline and failure
samples genotyped, 3 mutations were present at significantly
higher rates in the failure samples (table 3), the K103N and
Y181C mutations associated with NvpR and the M184V mutation associated with 3TCR. A significantly higher rate of these
mutations in failure samples was substantiated further by using
multifactorial simulation hotspot analysis of the entire set of
data and comparing the rate of each mutation at the baseline
versus failure time points (P ! .0001 for K103N, P p .002 for
Y181C, and P p .0006 for M184V). No primary NvpR mutations were detected at virologic failure among children in
study arm B, which lacked Nvp. Primary 3TCR mutations were
detected at virologic failure in 4 children in study arms A and
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Table 3. Comparison of numbers of children
(n p 52) with the K103N, Y181C, or M184V
mutations in baseline and failure samples.
Mutation
K103N
Y181C
M184V

At
baseline

After
treatment failure

1 (2)
0 (0)
3 (6)

17 (33)
11 (21)
18 (35)

a

P

!.0001

.0005
.0004

NOTE. Data are no. (%) of children.
a
P values were obtained by a nonparametric resampling method.

C, which lacked 3TC. Two of these children had the V118I
mutation, and 2 had the M184V mutation. All 4 children received ddI before study entry. These mutations were detected
at baseline in 2 of the 3 children for whom a baseline sample
was available.
We next analyzed whether children who received 3-drug Nvpcontaining regimens (study arms A and C) were more likely to
develop NvpR mutations than those who received the 4-drug
regimen (study arm D). Of the children who received 3-drug
regimens, 27 (84%) of 32 had ⭓1 primary NvpR mutation at the
time of virologic failure. In contrast, only 2 (29%) of 7 children
who received the 4-drug regimen (study arm D) had those mutations (P p .007, Fisher’s exact test). We performed a similar
analysis to compare the rate of selection of primary 3TCR mutations in children who received 3-drug 3TC-containing regimens
(study arms B ⫹ Q) versus the 4-drug 3TC-containing regimen
(study arm D). The number of children in these 2 groups who
had ⭓1 3TCR mutation at the time of virologic failure was not
statistically significant (P p .32, Fisher’s exact test).

Analysis of Late Failure Samples

An amendment added to PACTG 377 allowed children in
the failure group to remain on their initial study regimen, provided that their HIV-1 RNA levels remained !100,000 copies/
mL. We evaluated whether continued treatment after an initial
virologic failure led to increased selection of drug resistance
mutations. In most cases, children who were maintained on
their study regimen after an initial virologic failure were still
receiving their initial study regimen at week 48. For those children, we analyzed samples collected at week 48. For children
whose treatment regimen was changed or discontinued before
week 48, samples were collected within 1 week of a discontinuation or change in study therapy. In a few cases, PCR amplification was unsuccessful because of a low virus load. In those
cases, a sample collected no more than 4 weeks earlier, while
the child was still on the study regimen, was analyzed.
Late failure samples were available and analyzed from 35
children (table 1). Of these 35 children, 27 also had baseline
samples and samples from their initial virologic failure analyzed. For the 27 children, the mean time between collection
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of baseline samples and the late failure sample was 40 weeks
(range, 20–48 weeks), and the mean time between collection of
samples from the initial virologic failure and late failure was
26.8 weeks (range, 9–41.7 weeks). We found that 11 (40.7%)
of these children developed ⭓1 new primary mutation at the
late failure time point (not present in baseline or initial failure
samples). Those mutations were associated with 3TCR (M184V
[n p 3]), NvpR (K103N [n p 3], Y181C and Y188L [n p 1
each] and G190A [n p 2]), RtvR (V82A [n p 1]), and NfvR
(D30N and V82A [n p 1 each], and L90M [n p 4]). Four children had ⭓2 new primary mutations at late failure. We saw no
association between the presence of primary mutations at the
time of virologic failure and the development of additional primary mutations at late failure; however, the number of children
in that analysis was small.

Discussion
We describe the analysis of HIV-1 drug resistance mutations
among a large cohort of children enrolled in the PACTG 377
protocol. Many of these children had been treated with antiretroviral nucleoside RT inhibitors (nRTIs) before enrollment in
the trial. Consistent with treatment histories of children in this
cohort, we found a high rate of primary mutations associated
with resistance to the nRTIs, Zdv, ddI, and ddC. However, none
of the baseline mutations were associated with a higher rate of
virologic failure. Of interest, many of the children had the RT
mutations E44D and V118I at study entry. Those mutations were
probably selected during previous treatment with Zdv and ddI
and are associated with low-to-moderate 3TCR when ZdvR mutations also are present [16]. Sixteen of the children who were
randomized to one of the 3TC-containing study arms had either
E44D or V118I in combination with ⭓1 ZdvR mutation at baseline. However, children with these baseline mutation patterns did
not experience a significantly higher rate of virologic failure than
did children who lacked these mutations.
Previous studies have demonstrated that HIV-1 with drug
resistance mutations may have reduced replicative capacity
when the drug is absent [17–19]. For example, decreased fitness
has been observed for HIV-1 with the M184V mutation [20–22].
We found that children who had any primary resistance mutation at baseline had consistently greater reductions in virus
loads over the course of the 48-week study than did children
without these mutations. The majority of primary resistance
mutations present at baseline were ZdvR mutations. This effect
was observed in children who received Nvp-containing regimens in PACTG 377 but was not seen in the children who did
not receive Nvp. This suggests that Nvp hypersusceptibility
may play a role in the greater reduction in virus load seen in
children with baseline resistance mutations. Alternatively, the
presence of drug resistance mutations in HIV-1 may lower the
replicative capacity of the virus. This finding suggests that the
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presence of drug resistance mutations may actually improve the
virologic response to therapy in children who are under treatment with other antiretroviral drugs. This interesting finding is
not completely unexpected and merits further investigation.
Our analysis of HIV-1 from samples collected at the time of
virologic failure revealed a high rate of selection of HIV-1 with
primary NvpR and 3TCR mutations. An important observation
from this study was that the rate of primary NvpR mutations
at the time of virologic failure was significantly higher for children receiving 3-drug versus 4-drug Nvp-containing regimens.
This suggests that the addition of a fourth drug to the treatment
regimen may provide additional potency and therefore slow
selection of NvpR variants. This may explain the better virologic
response in the 4-drug arm (study arm D) in PACTG 377.
Continued treatment after virologic failure also was associated
with selection of additional primary drug resistance mutations
associated with resistance to RT inhibitors. In several cases,
children developed resistance to ⭓2 of their study drugs.
Mutations associated with resistance to the protease inhibitors,
Nfv and Rtv, were detected rarely at the time of virologic failure.
Only 2 children had the D30N mutation at the failure time point,
and none had the L90M mutation. Furthermore, additional protease inhibitor mutations (D30N, L90M, or V82A) were detected
in only 5 (19%) of 27 children who were maintained on their
initial study regimen after an initial virologic failure. In contrast,
mutations associated with resistance to protease inhibitors have
been observed frequently at the time of virologic failure in adults
receiving Nfv [23, 24]. Furthermore, in a phase I study of Nfv
in a pediatric cohort [25], 8 (73%) of 11 children who experienced
virologic failure after an initial decrease in virus load from baseline developed the D30N mutation, and 1 had a new L90M
mutation [26]. In that phase I study, many patients, including 5
of the 9 with new protease inhibitor mutations, did not have new
nRTIs added to their treatment regimens when Nfv therapy was
begun. It is not clear why mutations associated with resistance
to protease inhibitors were so infrequent in the PACTG 377
cohort, but all patients in this study received 2 or 3 new RT
inhibitors with the protease inhibitors.
Our findings demonstrate that genotypic resistance is frequent in children receiving highly active regimens with less than
complete viral suppression. In this cohort, resistance was more
frequent among children receiving 3-drug regimens than in
those receiving 4-drug regimens. The relative and possibly interacting roles of adherence, regimen potency, and pharmacokinetics in selection and emergence of drug-resistant HIV-1
in children remain to be determined.
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